$UTMD
Utah Medical Products Inc

2023 Q4 Form 10-Q Financial Statement

#000181188423000021 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $12.33M $12.51M
YoY Change -9.15% -3.47%
Cost Of Revenue $5.235M $5.146M
YoY Change -0.23% 7.91%
Gross Profit $7.098M $7.359M
YoY Change -14.76% -10.1%
Gross Profit Margin 57.55% 58.85%
Selling, General & Admin $3.008M $3.252M
YoY Change -4.02% 10.88%
% of Gross Profit 42.38% 44.19%
Research & Development $146.0K $138.0K
YoY Change 18.7% 23.21%
% of Gross Profit 2.06% 1.88%
Depreciation & Amortization $1.025M $1.770M
YoY Change -41.02% 2.19%
% of Gross Profit 14.44% 24.05%
Operating Expenses $3.154M $3.390M
YoY Change -3.16% 11.33%
Operating Profit $3.944M $3.969M
YoY Change -22.21% -22.8%
Interest Expense $3.036M
YoY Change 359.3%
% of Operating Profit 76.98%
Other Income/Expense, Net -$1.963M $812.0K
YoY Change 1302.14% 310.1%
Pretax Income $5.017M $4.781M
YoY Change -10.27% -10.45%
Income Tax $731.0K $846.0K
% Of Pretax Income 14.57% 17.7%
Net Earnings $4.286M $3.935M
YoY Change -5.91% -8.06%
Net Earnings / Revenue 34.75% 31.47%
Basic Earnings Per Share $1.08
Diluted Earnings Per Share $1.18 $1.08
COMMON SHARES
Basic Shares Outstanding 3.630M shares 3.630M shares
Diluted Shares Outstanding 3.639M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $92.87M $88.20M
YoY Change 23.74% 26.89%
Cash & Equivalents $92.87M $88.21M
Short-Term Investments
Other Short-Term Assets $428.0K $442.0K
YoY Change -16.89% 14.21%
Inventory $9.582M $9.709M
Prepaid Expenses
Receivables $3.391M $3.487M
Other Receivables $0.00 $0.00
Total Short-Term Assets $106.3M $101.8M
YoY Change 18.18% 20.9%
LONG-TERM ASSETS
Property, Plant & Equipment $10.55M $10.35M
YoY Change 3.2% 5.01%
Goodwill $13.69M $13.42M
YoY Change 2.53% 4.3%
Intangibles $4.946M $5.626M
YoY Change -52.34% -49.05%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $29.19M $29.40M
YoY Change -14.04% -13.97%
TOTAL ASSETS
Total Short-Term Assets $106.3M $101.8M
Total Long-Term Assets $29.19M $29.40M
Total Assets $135.5M $131.2M
YoY Change 9.35% 10.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $769.0K $511.0K
YoY Change -36.86% -60.36%
Accrued Expenses $3.941M $3.666M
YoY Change -16.89% -26.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.710M $4.177M
YoY Change -20.97% -33.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $993.0K $1.256M
YoY Change -37.82% -25.01%
Total Long-Term Liabilities $993.0K $1.256M
YoY Change -37.82% -25.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.710M $4.177M
Total Long-Term Liabilities $993.0K $1.256M
Total Liabilities $7.145M $7.541M
YoY Change -25.73% -26.26%
SHAREHOLDERS EQUITY
Retained Earnings $138.3M $135.1M
YoY Change 9.79% 10.3%
Common Stock $630.0K $557.0K
YoY Change 119.51% 492.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.3M $123.7M
YoY Change
Total Liabilities & Shareholders Equity $135.5M $131.2M
YoY Change 9.35% 10.83%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $4.286M $3.935M
YoY Change -5.91% -8.06%
Depreciation, Depletion And Amortization $1.025M $1.770M
YoY Change -41.02% 2.19%
Cash From Operating Activities $5.331M $5.120M
YoY Change -6.14% -8.39%
INVESTING ACTIVITIES
Capital Expenditures $89.00K $190.0K
YoY Change 134.21% -159.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$89.00K -$190.0K
YoY Change 134.21% -40.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.075M -1.030M
YoY Change 16.85% -0.19%
NET CHANGE
Cash From Operating Activities 5.331M 5.120M
Cash From Investing Activities -89.00K -190.0K
Cash From Financing Activities -1.075M -1.030M
Net Change In Cash 4.167M 3.900M
YoY Change -11.75% -7.93%
FREE CASH FLOW
Cash From Operating Activities $5.331M $5.120M
Capital Expenditures $89.00K $190.0K
Free Cash Flow $5.242M $4.930M
YoY Change -7.09% -16.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12575
dei Entity Registrant Name
EntityRegistrantName
UTAH MEDICAL PRODUCTS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0342734
dei Entity Address Address Line1
EntityAddressAddressLine1
7043 South 300 West
dei Entity Address City Or Town
EntityAddressCityOrTown
Midvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84047
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
566-1200
dei Security12b Title
Security12bTitle
Common stock, $0.01 par value
dei Trading Symbol
TradingSymbol
UTMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3629525 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88209000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75052000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3487000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5538000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
9709000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8814000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
442000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
515000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
101847000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
89919000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10346000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10224000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
13424000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
13354000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
53042000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
52755000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
47416000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
42378000 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5626000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10377000 usd
CY2023Q3 us-gaap Assets
Assets
131243000 usd
CY2022Q4 us-gaap Assets
Assets
123874000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
511000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1218000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3666000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4742000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4177000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5960000 usd
CY2023Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1196000 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1514000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1256000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1256000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
305000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
341000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
607000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
549000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
7541000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
9620000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3629000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3629000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3628000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3628000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-11999000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-12039000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
521000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
251000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
135144000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
126006000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123702000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
114254000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131243000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123874000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12505000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12955000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37891000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38707000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5146000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4769000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14951000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14838000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
7359000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
8186000 usd
us-gaap Gross Profit
GrossProfit
22940000 usd
us-gaap Gross Profit
GrossProfit
23869000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3252000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2933000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9693000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8779000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
414000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
370000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3390000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3045000 usd
us-gaap Operating Expenses
OperatingExpenses
10107000 usd
us-gaap Operating Expenses
OperatingExpenses
9149000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3969000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
5141000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
12833000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
14720000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
812000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
198000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2239000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
348000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4781000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5339000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15072000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15068000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
846000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1059000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2723000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3150000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3935000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
4280000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
us-gaap Profit Loss
ProfitLoss
11918000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.26
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3625000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3641000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3639000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3634000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3638000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3650000 shares
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1012000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2572000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
41000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5377000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2923000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1708000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12390000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6541000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
us-gaap Profit Loss
ProfitLoss
11918000 usd
us-gaap Depreciation
Depreciation
465000 usd
us-gaap Depreciation
Depreciation
454000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4824000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4837000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-31000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
21000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
39000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
39000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-284000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-409000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
153000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
121000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
12000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2133000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1059000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
925000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2065000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-712000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
540000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1093000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1075000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
4600000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3549000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16949000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15467000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
771000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-549000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-780000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
43000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2495000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
3211000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2112000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3094000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4564000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-149000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1586000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13157000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8537000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75052000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60974000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88209000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69511000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3489000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3502000 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
121762000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 usd
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
53000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1012000 usd
CY2023Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1071000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3935000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123702000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
114254000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
117000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
153000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
41000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
3212000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123702000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107471000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000 usd
CY2022Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
38000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2572000 usd
CY2022Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1051000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
4280000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
108185000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107138000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
121000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-2495000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5377000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
3162000 usd
us-gaap Profit Loss
ProfitLoss
11918000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
108185000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2338000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1896000 usd
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1654000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1193000 usd
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
5717000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5725000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
9709000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8814000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121000 usd
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12505000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37891000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3935000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
4280000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
us-gaap Profit Loss
ProfitLoss
11918000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3625000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3641000 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10000 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3639000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3634000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3638000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3650000 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.26

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001811884-23-000021-index-headers.html Edgar Link pending
0001811884-23-000021-index.html Edgar Link pending
0001811884-23-000021.txt Edgar Link pending
0001811884-23-000021-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
utmd-20230930.htm Edgar Link pending
utmd-20230930.xsd Edgar Link pending
utmd_ex31z1.htm Edgar Link pending
utmd_ex31z2.htm Edgar Link pending
utmd_ex32z1.htm Edgar Link pending
utmd_ex32z2.htm Edgar Link pending
utmd-20230930_def.xml Edgar Link unprocessable
utmd-20230930_cal.xml Edgar Link unprocessable
utmd-20230930_lab.xml Edgar Link unprocessable
utmd-20230930_pre.xml Edgar Link unprocessable
utmd-20230930_htm.xml Edgar Link completed